Rabbit Recombinant Monoclonal INPP4B antibody - conjugated to APC.
IgG
Rabbit
APC
Ex: 650nm, Em: 660nm
pH: 7.4
Preservative: 0.02% Sodium azide
Constituents: 98% PBS, 1% BSA
Liquid
Monoclonal
| Application | Reactivity | Dilution info | Notes |
|---|---|---|---|
Application Target Binding Affinity | Reactivity Expected | Dilution info - | Notes - |
Application Antibody Labelling | Reactivity Expected | Dilution info - | Notes - |
Select an associated product type
Catalyzes the hydrolysis of the 4-position phosphate of phosphatidylinositol 3,4-bisphosphate, inositol 1,3,4-trisphosphate and inositol 3,4-trisphosphate (PubMed:24070612, PubMed:24591580). Plays a role in the late stages of macropinocytosis by dephosphorylating phosphatidylinositol 3,4-bisphosphate in membrane ruffles (PubMed:24591580). The lipid phosphatase activity is critical for tumor suppressor function. Antagonizes the PI3K-AKT/PKB signaling pathway by dephosphorylating phosphoinositides and thereby modulating cell cycle progression and cell survival (PubMed:19647222, PubMed:24070612).
Inositol polyphosphate 4-phosphatase type II, INPP4B
Rabbit Recombinant Monoclonal INPP4B antibody - conjugated to APC.
Inositol polyphosphate 4-phosphatase type II, INPP4B
IgG
Rabbit
APC
Ex: 650nm, Em: 660nm
pH: 7.4
Preservative: 0.02% Sodium azide
Constituents: 98% PBS, 1% BSA
Liquid
Monoclonal
EPR3108Y
Affinity purification Protein A
Blue Ice
1-2 weeks
+4°C
+4°C
Upon delivery aliquot
Avoid freeze / thaw cycle, Store in the dark
This conjugated primary antibody is “made to order” and it is released using a quantitative quality control method that ensures binding affinity and labelling efficiency of the conjugate. Via leveraging the power of the Lightning-Link® conjugation technology, Abcam will deliver highly consistent recombinant conjugates in <2 weeks, giving you access to an ever growing portfolio of antibody-label combinations.
For suitable applications and species reactivity, please refer to the unconjugated version of this clone.
This product is FOR RESEARCH USE ONLY. For commercial use, please contact partnerships@abcam.com.
This conjugated primary antibody is released using a quantitative quality control method that evaluates binding affinity post-conjugation and efficiency of antibody labeling.
For suitable applications and species reactivity, please refer to the unconjugated version of this clone. This conjugated antibody is eligible for the Abcam trial program.
Our RabMAb® technology is a patented hybridoma-based technology for making rabbit monoclonal antibodies. For details on our patents, please refer to RabMAb® patents.
This product is a recombinant monoclonal antibody, which offers several advantages including:
For more information, read more on recombinant antibodies.
This supplementary information is collated from multiple sources and compiled automatically.
INPP4B also known as inositol polyphosphate-4-phosphatase type II has a molecular mass of approximately 105 kDa. This enzyme primarily localizes in the cytoplasm but also presents in the nucleus. It catalyzes the hydrolysis of the 4-phosphate group from phosphoinositides converting phosphatidylinositol (34)-bisphosphate (PI(34)P2) to phosphatidylinositol 3-phosphate (PI3P). INPP4B expression is noticeable in various tissues including the prostate thyroid and breast suggesting its diverse roles in different physiological processes.
INPP4B participates in regulating intracellular signaling pathways and maintaining cellular homeostasis. It is a negative regulator of the PI3K/AKT signaling cascade a critical pathway controlling cell growth proliferation survival and metabolism. INPP4B acts as a tumor suppressor modulating signals that impact cellular transformation and tumorigenesis. While not known to form a complex itself it indirectly influences complexes within the cascade through its regulatory functions.
INPP4B contributes to the PI3K/AKT and mTOR pathways. It regulates PI3K/AKT signaling by decreasing levels of PI(34)P2 therefore modulating AKT activity. This action makes it an essential component in controlling mTOR signaling which affects protein synthesis and autophagy. INPP4B closely interacts with other signaling proteins like PTEN also a phosphatase which further lowers PI3K signaling by dephosphorylating PI(345)P3 to PI(45)P2.
INPP4B has notable links to cancer and insulin resistance. In some cancers like breast and prostate reduced INPP4B expression correlates with increased aggressive phenotypic markers and poor outcomes indicating its tumor-suppressive role. Its regulation of the PI3K/AKT pathway connects it to insulin signaling where dysregulated pathways can lead to insulin resistance a critical factor in type 2 diabetes. INPP4B interacts with proteins involved in these diseases like AKT and PTEN which further influence and exacerbate the pathology in these conditions.
We have tested this species and application combination and it works. It is covered by our product promise.
We have not tested this specific species and application combination in-house, but expect it will work. It is covered by our product promise.
This species and application combination has not been tested, but we predict it will work based on strong homology. However, this combination is not covered by our product promise.
We do not recommend this combination. It is not covered by our product promise.
We are dedicated to supporting your work with high quality reagents and we are here for you every step of the way should you need us.
In the unlikely event of one of our products not working as expected, you are covered by our product promise.
Full details and terms and conditions can be found here:
Terms & Conditions.
Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.
For licensing inquiries, please contact partnerships@abcam.com